U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Non-Measurable Lesion

MedGen UID:
277419
•Concept ID:
C1334988
•
Finding

Definition

A neoplasm for which no exact measurement may be obtained. This may be due to a size below detection, an invasive presentation, or pertain to an effusion or ascites. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVNon-Measurable Lesion

Professional guidelines

PubMed

Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1).
Armato SG 3rd, Nowak AK
J Thorac Oncol 2018 Jul;13(7):1012-1021. Epub 2018 May 9 doi: 10.1016/j.jtho.2018.04.034. PMID: 29753121
Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W
BMC Res Notes 2015 Oct 26;8:609. doi: 10.1186/s13104-015-1565-2. PMID: 26502722Free PMC Article
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J
Eur J Cancer 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. PMID: 19097774

Recent clinical studies

Etiology

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y
Lancet Oncol 2019 Nov;20(11):1506-1517. Epub 2019 Sep 30 doi: 10.1016/S1470-2045(19)30626-6. PMID: 31582355
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ
Lancet 2016 Dec 17;388(10063):2997-3005. Epub 2016 Nov 29 doi: 10.1016/S0140-6736(16)32389-3. PMID: 27908454
Cisplatin, adriamycin and ifosfamide-based combination chemotherapy for gynecological cancers derived from the extended müllerian system.
Nishida T, Nagasue N, Izumi S, Sakihama H, Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi 1990 Feb;42(2):193-8. PMID: 1690254

Diagnosis

Cisplatin, adriamycin and ifosfamide-based combination chemotherapy for gynecological cancers derived from the extended müllerian system.
Nishida T, Nagasue N, Izumi S, Sakihama H, Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi 1990 Feb;42(2):193-8. PMID: 1690254

Therapy

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y
Lancet Oncol 2019 Nov;20(11):1506-1517. Epub 2019 Sep 30 doi: 10.1016/S1470-2045(19)30626-6. PMID: 31582355
Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).
Noguchi S, Ellis MJ, Robertson JFR, Thirlwell J, Fazal M, Shao Z
Breast Cancer 2018 May;25(3):356-364. Epub 2018 Feb 15 doi: 10.1007/s12282-018-0838-8. PMID: 29450827
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ
Lancet 2016 Dec 17;388(10063):2997-3005. Epub 2016 Nov 29 doi: 10.1016/S0140-6736(16)32389-3. PMID: 27908454
Cisplatin, adriamycin and ifosfamide-based combination chemotherapy for gynecological cancers derived from the extended müllerian system.
Nishida T, Nagasue N, Izumi S, Sakihama H, Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi 1990 Feb;42(2):193-8. PMID: 1690254

Prognosis

Cisplatin, adriamycin and ifosfamide-based combination chemotherapy for gynecological cancers derived from the extended müllerian system.
Nishida T, Nagasue N, Izumi S, Sakihama H, Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi 1990 Feb;42(2):193-8. PMID: 1690254

Clinical prediction guides

Cisplatin, adriamycin and ifosfamide-based combination chemotherapy for gynecological cancers derived from the extended müllerian system.
Nishida T, Nagasue N, Izumi S, Sakihama H, Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi 1990 Feb;42(2):193-8. PMID: 1690254

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...